openPR Logo
Press release

Antibody Drug Conjugates Market Market Estimated to Cross (Revenues) by 2025

08-29-2017 08:05 AM CET | Health & Medicine

Press release from: Persistence Market Research

Antibody Drug Conjugates Market Market Estimated to Cross

Antibody drug conjugates have therapeutic potential and contains both technological and developmental challenges. Antibody drug conjugates are considered to be the new age of therapeutic agent. They combine the targeting ability of monoclonal antibody and the target specific cell killing ability of cytotoxic drugs. The success of this technology has become possible only with the increasing technological advancements.

A sample of this report is available upon request @
http://www.persistencemarketresearch.com/samples/13360

Antibody drug conjugates is the new class of therapeutic agent that is gaining attention from both large and small pharmaceutical companies. The potency of the cytotoxic drug in antibody drug conjugate is 100-1000 fold more than the potency of cytotoxic drug when it acts alone. Though this technology provides presence to maximum large pharmaceuticals companies, the capabilities for the development of ADC still lies with very few companies.

There are many products under pipeline. Most development today has been carried out under license agreements. There are only three antibody drug conjugates that have received approval from the U.S. Food and Drug Administration (FDA).

The first drug Mylotarg among them was withdrawn from the market by its manufacturers in June 2010. It was used to treat acute myelogenous leukemia but a clinical trial showed that the drug has only increased the mortality rate among the acute myelogenous leukemia patient and had no benefit over the conventional therapy. Therefore the antibody drug conjugate market is segmented to only two approved products.

The global market for antibody drug conjugates is expected to be driven by the advancement in medical technology. The key drivers of the market are the increasing cases prevalence of cancer, growing ageing population and increase in obese population. Moreover, the increasing research activities on antibody therapies, preclinical research, more research on advanced drug discoveries and increasing research on oncology diseases and the growing collaboration between research institutes,

Biotechnology and Biopharmaceuticals companies is also acting as a fuel to the market and is expected to drive the market of antibody drug conjugates within the forecast period of 2016-2024. However, the high cost of the procedures and the lack of fund can be the restraint for the growth of this market.

To view TOC of this report is available upon request @
http://www.persistencemarketresearch.com/toc/13360

The number of companies developing methods for antibody drug conjugates technology has not significantly changed in recent years. The increasing investment by the pharmaceutical and Biotechnology companies is expected to drive the market.

Based on the product type the market is segmented to Adcertis and Kadcyla. Adcetris (brentuximab vedotin) is drug indicated for patients suffering with classical Hodgkin lymphoma (HL) after failure from at least two multi-agent chemotherapy regimen in patient who are not auto-HSCT candidates or patient with failure of autologous hematopoietic stem cell transplantation, HL patients at high risk of relapse or progression as post- auto- HSCT consolidation and lymphoma patient after failure of at least one prior multi-agent chemotherapy.

Drugs was granted accelerated approval for Biologics License Application (BLA) by the U.S FDA for its usage in relapsed and refractory Hodgkin’s lymphoma and large cell lymphoma. Kadcyla (Trastuzumab emtansine) it is the first HER2-targeted treatment of its own kind for metastatic breast cancer. It contains two cancer- fighting drugs in one. It contains monoclonal antibody trastuzumab (the same monoclonal antibody in Herceptin) and chemotherapy drug. Kadcyla is treatment that targets HER2.

By end user, the global antibody drug conjugates market has been segmented into Hospitals, Specialized Cancer Centers, Academic Research Institutes, Biotechnology Companies, Biopharmaceutical Companies and others. Antibody drug conjugates are used in cancer cell therapy and for research and clinical trials.

By regional presence, antibody drug conjugates market is segmented into five key regions viz. North America, Latin America, Europe, Asia-Pacific, and the Middle East & Africa. North America will continue to dominate the antibody drug conjugates market as it has high experienced professionals and better healthcare facilities.

Europe is expected to hold second largest market share in global antibody drug conjugates market. The growing government initiatives and increasing number of Biotechnology and Biopharmaceutical companies in APAC is also driving the market of antibody drug conjugates in APAC.

Some of the major players in global antibody drug conjugates market include Genentech USA, Inc., Seattle Genetics, F. Hoffmann-La Roche Ltd and Takeda Pharmaceuticals.

Buy Now: You can now buy a single user license of the report @
http://www.persistencemarketresearch.com/checkout/13360

About Us
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.
To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact Us
Persistence Market Research
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353
Email: sales@persistencemarketresearch.com
Web: http://www.persistencemarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Antibody Drug Conjugates Market Market Estimated to Cross (Revenues) by 2025 here

News-ID: 687959 • Views:

More Releases from Persistence Market Research

Plastic Liner Market to Reach US$ 6.67 Bn by 2030, Expanding at 4.7% CAGR - Persistence Market Research
Plastic Liner Market to Reach US$ 6.67 Bn by 2030, Expanding at 4.7% CAGR - Pers …
➤ Overview of the Market The global plastic liner market has gained steady traction across multiple industries due to its cost-effectiveness, versatility, and protective characteristics. Plastic liners are widely used in agriculture, mining, construction, waste management, and packaging industries, where they serve as an essential barrier to prevent leakage, contamination, and material loss. These liners are manufactured using materials such as polyethylene (PE), polypropylene (PP), and PVC, offering superior resistance to
Returnable Plastic Crate Market to Reach US$ 2,665.1 Million by 2030 Fueled by Sustainability and Supply Chain Efficiency
Returnable Plastic Crate Market to Reach US$ 2,665.1 Million by 2030 Fueled by S …
➤ Overview of the Market The global returnable plastic crate market is gaining momentum as industries seek cost-effective and sustainable packaging solutions. These crates are widely used for transporting and storing perishable goods, beverages, pharmaceuticals, and industrial products due to their durability, stackability, and reusability. The shift from single-use packaging to eco-friendly alternatives has accelerated the adoption of returnable plastic crates across sectors. The market, valued at US$ 1,820.0 million in
US Thermal Power Market Expected to Reach US$ 251.9 Mn by 2031 with 2.4% CAGR Growth - Persistence Market Research
US Thermal Power Market Expected to Reach US$ 251.9 Mn by 2031 with 2.4% CAGR Gr …
➤Overview of the Market The US thermal power market plays a crucial role in the nation's energy mix, serving as a stable and reliable source of electricity despite the rise of renewables. Thermal power plants in the US rely primarily on coal, natural gas, and oil to generate electricity, with natural gas emerging as the dominant fuel source due to its affordability, efficiency, and lower carbon footprint compared to coal. According
Europe Medical Plastic Market to Reach US$ 17 Bn by 2032 Driven by Rising Healthcare Demand
Europe Medical Plastic Market to Reach US$ 17 Bn by 2032 Driven by Rising Health …
➤Overview of the Market The Europe medical plastic market is undergoing robust growth, fueled by increasing demand for lightweight, durable, and cost-effective materials in the healthcare sector. Medical plastics are widely used in devices, surgical instruments, diagnostic tools, implants, and packaging due to their high biocompatibility, versatility, and resistance to sterilization methods. With healthcare systems across Europe investing heavily in modernization and patient safety, the adoption of medical-grade plastics has gained

All 5 Releases


More Releases for Antibody

Evolving Market Trends In The Antibody Drug Conjugates Industry: Regulation On A …
The Antibody Drug Conjugates Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Expected Antibody Drug Conjugates Market Size During the Forecast Period? The market size for antibody drug conjugates has experienced rapid expansion in the past few years. It's projected to rise from
TIGIT Antibody Clinical Trials FDA Approval Market Size Anti TGIT Antibody Sales …
Anti TIGIT Antibodies Clinical Trials & Market Opportunity Outlook 2028 Report Highlights: • Anti TIGIT Antibodies In Clinical Trials: > 50 Antibodies • First Anti TIGIT Antibody To Get Approval Within Next 5 Years • Global Anti TIGIT Antibodies Clinical Pipeline Insight By Company, Indication and Phase • Insight On More Than 50 Anti TIGIT Antibodies In Clinical Trials • Anti TIGIT Antibodies Market Trends by Indication & Country • Global Anti TIGIT Antibodies Market Dynamics Download Report: https://www.kuickresearch.com/report-anti-tigit-antibody-anti-tigit-antibodies-fda-approved-tigit-antibody-tigit-inhibitors-tigit-drugs-approved-tigit-expression-tigit-ligand-tigit-gene In recent years, the global
Mammalian Polyclonal IgG Antibody Market, Mammalian Polyclonal IgG Antibody Mark …
"According to the research report, the global inspection machines market was valued at USD 845.21 million in 2022 and is expected to reach USD 1,437.59 million by 2032, to grow at a CAGR of 5.5% during the forecast period." Request Our Free Sample Report for Inspection Machines Market Insights and Emerging Trends @ https://www.polarismarketresearch.com/industry-analysis/inspection-machines-market/request-for-sample Report Overview Polaris Market Research, a leading global market research and consulting company, has recently published its latest report
Global Combination Antibody Therapy Market 2022: Antibody/Antibody Combination S …
The combination antibody therapy market is expected to experience significant growth in the coming years. Combination antibody therapy involves the use of two or more monoclonal antibodies (mAbs) in combination to treat various diseases, such as cancer, autoimmune disorders, and infectious diseases. Request For Free Sample Report of "Combination Antibody Therapy Market"@ https://www.persistencemarketresearch.com/samples/11740 Combination antibody therapy has several potential benefits over single-agent therapies, including increased efficacy, improved patient outcomes, and reduced toxicity.
Global Combination Antibody Therapy Market 2022: Antibody/Antibody Combination S …
Combination antibody therapy involves the use of two or more antibodies to target and treat a specific disease or condition. This type of therapy is often used in cancer treatment, as it can be more effective at targeting and killing cancer cells than single-antibody therapies. Combination antibody therapy can also be used to treat a range of other diseases and conditions, including autoimmune diseases, infectious diseases, and allergic conditions. Request For
Procalcitonin Antibody Market Report 2018: Segmentation by Type (Polyclonal Proc …
Global Procalcitonin Antibody market research report provides company profile for Ningbo Medicalsystem Biotechnology, Snibe, Vazyme Biotech, Getein Biotech, Hotgen Biotech, Lumigenex, Shanghai Medicine'nest Pharmaceutical, Thermo Fisher, Roche Diagnostics, bioMerieux, HyTest, Wondfo and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR for